Medications for Anaplastic Lymphoma Kinase Fusion Oncogene Positive Nonsmall Cell Lung Cancer

3 results

  • alecensa

    (ALECTINIB HYDROCHLORIDE)
    Genentech, Inc.
    ALECENSA is indicated for adjuvant treatment in adults with resected ALK-positive non-small cell lung cancer (NSCLC) and for the treatment of adult patients with metastatic ALK-positive NSCLC, both detected by an FDA-approved test.

  • alunbrig

    (brigatinib)
    Takeda Pharmaceuticals America, Inc.
    ALUNBRIG is indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) confirmed by an FDA-approved test.

  • xalkori

    (CRIZOTINIB)
    Pfizer Laboratories Div Pfizer Inc
    XALKORI is indicated for adult patients with ALK- or ROS1-positive metastatic non-small cell lung cancer, and for pediatric patients (1 year and older) with relapsed or refractory systemic ALK-positive anaplastic large cell lymphoma. It is also approved for unresectable, recurrent, or refractory ALK-positive inflammatory myofibroblastic tumors in both adults and pediatric patients.